Please assess the completion status of the following clinical trial:

Trial Title: Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 24 months of age or younger at randomization (child must be randomized on or before his/her 24-month birthday) with a diagnosis of chronic lung disease (CLD) of prematurity requiring medical intervention/management (i.e., supplemental oxygen, bronchodilators, or diuretics) within 6 months before randomization~OR:~* 35 weeks gestational age or less at birth and 6 months of age or younger at randomization (children were to be randomized on or before his/her 6-month birthday)~Exclusion Criteria:~* Hospitalization at the time of randomization (unless discharge was anticipated within 10 days)~* Mechanical ventilation or other mechanical support (including continuous positive airways pressure \[CPAP\])~* Life expectancy \< 6 months~* Active RSV infection (a child with signs/symptoms of respiratory infection must have had negative RSV testing)~* Known renal impairment~* Known hepatic dysfunction~* Chronic seizure or evolving or unstable neurologic disorder~* Congenital heart disease \[CHD\] (children with uncomplicated CHD \[e.g., patent ductus arterious (PDA), small septal defect\] and children with complicated CHD that were currently anatomically and hemodynamically normal could be enrolled)~* Known immunodeficiency~* Mother with HIV infection (unless the child has been proven to be not infected)~* Known allergy to Ig products~* Receipt of palivizumab, RSV-IGIV, or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B IG, IVIG, VZIG) within 3 months prior to randomization~* Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)~* Previous receipt of RSV vaccines~* Participation in other investigational drug product studies

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- palivizumab (Type: ACTIVE_COMPARATOR): 15 mg/kg administered intramuscularly for 5 monthly doses
- motavizumab (MEDI-524) (Type: EXPERIMENTAL): 15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses

Based on this trial design, predict the completion outcome and termination type (if applicable).